Screener
Opus Genetics IRD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -359.1%+112pp | -271.9%+293pp | -445.4%-93.7pp | -420.7%-329pp | -471%-407pp | |
| Net margin | -892.4%-463pp | -349.3%+174pp | -466.1%-142pp | -377.9%-292pp | -429.4%-370pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.3×+0.1× | 0.4×+0.2× | 0.4×0.0× | 0.3×-0.1× | |
| Liquidity | ||||||
| Current ratio | 7.1×+5.2× | 6.4×+3.2× | 1.2×-5.4× | 1.9×-8.8× | 2×-7.0× | |
| Per Share | ||||||
| Book value per share | -$0.53-452% | $0.25-2.0% | $0.08-93.6% | $0.28-82.5% | $0.15-92.0% | |
| Valuation | ||||||
| Market capitalization | $375.21M+248% | $138.62M+269% | $98.85M— | $55.1M— | $44.15M— | |
| Price / sales | 31.3×+23.9× | 9.8×+6.3× | 6.8×— | 3.6×— | 3.2×— |
FAQ
- Where do Opus Genetics's ratios come from?
- Every ratio is computed from Opus Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
